Kura Oncology, Inc.
Kura Oncology, Inc. (KURA) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · KURA · as of Jun 8, 2026
Activity summary
Buy transactions
3
P-Purchase only
Sell transactions
33
12 Months
Buy/Sell ratio
0.09
Buy/Sell (by trades)
Overall sentiment
Kura Oncology, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
KURA insider buying and selling by quarter
KURA insider selling · KURA insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · KURA ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
KURA executive sell shares · KURA board member insider trading · KURA insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 21, 2026 | Powl Brian T. Chief Commercial Officer | Sale | 10,000 | $110K | Form 4 |
| May 19, 2026 | Powl Brian T. Chief Commercial Officer | Sale | 339 | $3K | Form 4 |
| May 19, 2026 | FORD KATHLEEN COO | Sale | 2,257 | $20K | Form 4 |
| May 18, 2026 | Bair Teresa Brophy Chief Legal Officer | Sale | 2,256 | $21K | Form 4 |
| Mar 23, 2026 | WILSON TROY EDWARD President and CEO · Director | Option | 6,103 | $38K | Form 4 |
| Mar 18, 2026 | Malley Thomas Director | Option | 10,000 | $31K | Form 4 |
| Jan 27, 2026 | Powl Brian T. Chief Commercial Officer | Sale | 4,842 | $41K | Form 4 |
| Jan 27, 2026 | Powl Brian T. Chief Commercial Officer | Sale | 1,572 | $13K | Form 4 |
| Jan 27, 2026 | FORD KATHLEEN COO | Sale | 1,813 | $15K | Form 4 |
| Jan 27, 2026 | Leoni Mollie Chief Medical Officer | Sale | 3,655 | $31K | Form 4 |
| Jan 27, 2026 | Leoni Mollie Chief Medical Officer | Sale | 2,233 | $19K | Form 4 |
| Jan 27, 2026 | Leoni Mollie Chief Medical Officer | Sale | 951 | $8K | Form 4 |
| Jan 27, 2026 | Leoni Mollie Chief Medical Officer | Sale | 1,341 | $11K | Form 4 |
| Jan 27, 2026 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | 2,226 | $19K | Form 4 |
| Jan 27, 2026 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | 1,114 | $9K | Form 4 |
| Jan 27, 2026 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | 695 | $6K | Form 4 |
| Jan 27, 2026 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | 2,226 | $19K | Form 4 |
| Jan 27, 2026 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Sale | 881 | $7K | Form 4 |
| Jan 27, 2026 | Burrows Francis Chief Scientific Officer | Sale | 1,311 | $11K | Form 4 |
| Jan 27, 2026 | Bair Teresa Brophy Chief Legal Officer | Sale | 4,096 | $35K | Form 4 |
| Jan 27, 2026 | Bair Teresa Brophy Chief Legal Officer | Sale | 2,335 | $20K | Form 4 |
| Jan 27, 2026 | Bair Teresa Brophy Chief Legal Officer | Sale | 4,777 | $40K | Form 4 |
| Jan 2, 2026 | Leoni Mollie Chief Medical Officer | Award | 50,000 | — | Form 4 |
| Jan 2, 2026 | DOYLE THOMAS JAMES SVP, Finance & Accounting | Award | 21,250 | — | Form 4 |
| Jan 2, 2026 | FORD KATHLEEN COO | Award | 50,000 | — | Form 4 |
Powl Brian T.
Chief Commercial Officer
Date
May 21
Shares
10,000
Price
$11.00
Value
$110K
Powl Brian T.
Chief Commercial Officer
Date
May 19
Shares
339
Price
$9.21
Value
$3K
Bair Teresa Brophy
Chief Legal Officer
Date
May 18
Shares
2,256
Price
$9.38
Value
$21K
WILSON TROY EDWARD
President and CEO · Director
Date
Mar 23
Shares
6,103
Price
$6.15
Value
$38K
Powl Brian T.
Chief Commercial Officer
Date
Jan 27
Shares
4,842
Price
$8.46
Value
$41K
Powl Brian T.
Chief Commercial Officer
Date
Jan 27
Shares
1,572
Price
$8.46
Value
$13K
DOYLE THOMAS JAMES
SVP, Finance & Accounting
Date
Jan 27
Shares
2,226
Price
$8.46
Value
$19K
DOYLE THOMAS JAMES
SVP, Finance & Accounting
Date
Jan 27
Shares
1,114
Price
$8.46
Value
$9K
DOYLE THOMAS JAMES
SVP, Finance & Accounting
Date
Jan 27
Shares
695
Price
$8.46
Value
$6K
DOYLE THOMAS JAMES
SVP, Finance & Accounting
Date
Jan 27
Shares
2,226
Price
$8.46
Value
$19K
DOYLE THOMAS JAMES
SVP, Finance & Accounting
Date
Jan 27
Shares
881
Price
$8.46
Value
$7K
Burrows Francis
Chief Scientific Officer
Date
Jan 27
Shares
1,311
Price
$8.46
Value
$11K
Bair Teresa Brophy
Chief Legal Officer
Date
Jan 27
Shares
4,096
Price
$8.46
Value
$35K
Bair Teresa Brophy
Chief Legal Officer
Date
Jan 27
Shares
2,335
Price
$8.46
Value
$20K
Bair Teresa Brophy
Chief Legal Officer
Date
Jan 27
Shares
4,777
Price
$8.46
Value
$40K
DOYLE THOMAS JAMES
SVP, Finance & Accounting
Date
Jan 2
Shares
21,250
Price
—
Value
—
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About KURA insider trading
KURA insider trades
Kura Oncology, Inc. (KURA) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including DOYLE THOMAS JAMES (SVP, Finance & Accounting), Powl Brian T. (Chief Commercial Officer), Bair Teresa Brophy (Chief Legal Officer). Over the past 12 months, 5 insiders have filed transactions with the SEC. KURA insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Kura Oncology, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
KURA insider trading · 5 questionsThe insiders of Kura Oncology, Inc. (KURA) include executives and directors such as DOYLE THOMAS JAMES (SVP, Finance & Accounting), Powl Brian T. (Chief Commercial Officer), Bair Teresa Brophy (Chief Legal Officer), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026